Pharmaceutical Technology1h
AbbVie to acquire Nimble Therapeutics for $200m
AbbVie has entered into a definitive agreement to acquire Nimble Therapeutics in a deal valued at $200m in cash.
Pharmaceutical Technology17h
Risk adjusted net present value: What is the current valuation of Otsuka’s Zipalertinib?
Zipalertinib is a small molecule commercialized by Otsuka, with a leading Phase III program in Non-Small Cell Lung Cancer.
Pharmaceutical Technology17h
Risk adjusted net present value: What is the current valuation of Ionis Pharmaceuticals’s Ulefnersen Sodium?
Ulefnersen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase III program in Amyotrophic Lateral Sclerosis.
Pharmaceutical Technology17h
Risk adjusted net present value: What is the current valuation of Artiva Biotherapeutics’s GCC-4001?
GCC-4001 is a cell therapy commercialized by Artiva Biotherapeutics, with a leading Phase II program in B-Cell Non-Hodgkin Lymphoma.
Pharmaceutical Technology17h
Risk adjusted net present value: What is the current valuation of Pfizer’s Ibuzatrelvir?
Ibuzatrelvir is a small molecule commercialized by Pfizer, with a leading Phase II program in Coronavirus Disease 2019 (COVID-19).
Pharmaceutical Technology17h
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences’s NBI-1076986?
NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders.
Pharmaceutical Technology17h
Risk adjusted net present value: What is the current valuation of Cardiol Therapeutics’s Cannabidiol 1?
Cannabidiol 1 is a small molecule commercialized by Cardiol Therapeutics, with a leading Phase II program in Pericarditis.
Pharmaceutical Technology17h
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Mazisotine?
Mazisotine is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Diabetic Neuropathic Pain.
Pharmaceutical Technology17h
Risk adjusted net present value: What is the current valuation of Prime Medicine’s PM-359?
PM-359 is a gene-modified cell therapy commercialized by Prime Medicine, with a leading Phase II program in Chronic Granulomatous Disease.
Pharmaceutical Technology17h
Risk adjusted net present value: What is the current valuation of Armata Pharmaceuticals’s APSA-02?
APSA-02 is a biologic commercialized by Armata Pharmaceuticals, with a leading Phase II program in Bacteremia.